(Q36141221)

12 August 2017

1 reference

title

Management of patients co-infected with hepatitis B virus and HIV. (English)

1 reference

12 August 2017

0 references

1 reference

1 reference

2

Vincent Soriano

1 reference

12 August 2017

Marina Núñez

1

1 reference

12 August 2017

1 June 2005

1 reference

Lancet Infectious Diseases

12 August 2017

1 reference

12 August 2017

5

1 reference

12 August 2017

6

1 reference

12 August 2017

374-382

1 reference

Hepatitis B virus infection

12 August 2017

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2805%2970141-9

7 January 2021

HIV-1, hepatitis B virus, and risk of liver-related mortality in the Multicenter Cohort Study (MACS).

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2805%2970141-9

7 January 2021

Prevalence of chronic hepatitis B and incidence of acute hepatitis B infection in human immunodeficiency virus-infected subjects

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2805%2970141-9

7 January 2021

HIV/HBV and HIV/HCV coinfection, and outcomes following highly active antiretroviral therapy

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2805%2970141-9

7 January 2021

Survival in patients with HIV infection and viral hepatitis B or C: a cohort study

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2805%2970141-9

7 January 2021

Treatment of chronic hepatitis B in the human immunodeficiency virus-infected patient: present and future

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2805%2970141-9

7 January 2021

A treatment algorithm for the management of chronic hepatitis B virus infection in the United States

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2805%2970141-9

7 January 2021

Chronic hepatitis B: update of recommendations

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2805%2970141-9

7 January 2021

Effect of Alpha-Interferon Treatment in Patients with Hepatitis B e Antigen-Positive Chronic Hepatitis B

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2805%2970141-9

7 January 2021

Long-term effects of interferon-alpha in five HIV-positive patients with chronic hepatitis B.

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2805%2970141-9

7 January 2021

Influence of HIV infection on the response to interferon therapy and the long-term outcome of chronic hepatitis B.

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2805%2970141-9

7 January 2021

Coinfection with hepatitis B and C or B, C and delta viruses results in severe chronic liver disease and responds poorly to interferon-alpha treatment.

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2805%2970141-9

7 January 2021

Treatment with interferons (including pegylated interferons) in patients with hepatitis B.

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2805%2970141-9

7 January 2021

Peginterferon alpha-2a (40 kDa): an advance in the treatment of hepatitis B e antigen-positive chronic hepatitis B.

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2805%2970141-9

7 January 2021

Pegylated interferon alfa-2b alone or in combination with lamivudine for HBeAg-positive chronic hepatitis B: a randomised trial

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2805%2970141-9

7 January 2021

Peginterferon alfa-2a alone, lamivudine alone, and the two in combination in patients with HBeAg-negative chronic hepatitis B.

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2805%2970141-9

7 January 2021

A randomized, controlled trial of combination therapy for chronic hepatitis B: comparing pegylated interferon-alpha2b and lamivudine with lamivudine alone

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2805%2970141-9

7 January 2021

Dual efficacy of lamivudine treatment in human immunodeficiency virus/hepatitis B virus-coinfected persons in a randomized, controlled study (CAESAR). The CAESAR Coordinating Committee

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2805%2970141-9

7 January 2021

Evaluation of chronic hepatitis B virus (HBV) infection in coinfected patients receiving lamivudine as a component of anti-human immunodeficiency virus regimens

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2805%2970141-9

7 January 2021

Long-term incidence of hepatitis B virus resistance to lamivudine in human immunodeficiency virus-infected patients

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2805%2970141-9

7 January 2021

Emtricitabine: an antiretroviral agent for HIV infection

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2805%2970141-9

7 January 2021

Molecular modeling and biochemical characterization reveal the mechanism of hepatitis B virus polymerase resistance to lamivudine (3TC) and emtricitabine (FTC).

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2805%2970141-9

7 January 2021

Week 48 resistance surveillance in two phase 3 clinical studies of adefovir dipivoxil for chronic hepatitis B.

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2805%2970141-9

7 January 2021

Tenofovir disoproxil fumarate

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2805%2970141-9

7 January 2021

Efficacy of tenofovir disoproxil fumarate in antiretroviral therapy-naive and -experienced patients coinfected with HIV-1 and hepatitis B virus

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2805%2970141-9

7 January 2021

Tenofovir treatment in patients with lamivudine-resistant hepatitis B mutants strongly affects viral replication

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2805%2970141-9

7 January 2021

Activity of tenofovir on hepatitis B virus replication in HIV-co-infected patients failing or partially responding to lamivudine.

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2805%2970141-9

7 January 2021

Tenofovir disoproxil fumarate therapy for chronic hepatitis B in human immunodeficiency virus/hepatitis B virus-coinfected individuals for whom interferon-alpha and lamivudine therapy have failed.

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2805%2970141-9

7 January 2021

An open-label study of tenofovir in HIV-1 and Hepatitis B virus co-infected individuals

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2805%2970141-9

7 January 2021

Tenofovir disoproxil fumarate in patients with HIV and lamivudine-resistant hepatitis B virus

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2805%2970141-9

7 January 2021

In vitro inhibition of hepadnavirus polymerases by the triphosphates of BMS-200475 and lobucavir.

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2805%2970141-9

7 January 2021

Entecavir is superior to lamivudine in reducing hepatitis B virus DNA in patients with chronic hepatitis B infection.

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2805%2970141-9

7 January 2021

Entecavir: a potent new antiviral drug for hepatitis B.

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2805%2970141-9

7 January 2021

Entecavir, FTC, L-FMAU, LdT and others

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2805%2970141-9

7 January 2021

Effects of extended lamivudine therapy in Asian patients with chronic hepatitis B. Asia Hepatitis Lamivudine Study Group

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2805%2970141-9

7 January 2021

Extended lamivudine treatment in patients with chronic hepatitis B enhances hepatitis B e antigen seroconversion rates: results after 3 years of therapy

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2805%2970141-9

7 January 2021

Resistance to adefovir dipivoxil therapy associated with the selection of a novel mutation in the HBV polymerase

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2805%2970141-9

7 January 2021

Selection of a hepatitis B virus strain resistant to adefovir in a liver transplantation patient.

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2805%2970141-9

7 January 2021

Early detection of viral resistance by determination of hepatitis B virus polymerase mutations in patients treated by lamivudine for chronic hepatitis B.

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2805%2970141-9

7 January 2021

Hepatitis B virus mutants associated with 3TC and famciclovir administration are replication defective

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2805%2970141-9

7 January 2021

The polymerase L528M mutation cooperates with nucleotide binding-site mutations, increasing hepatitis B virus replication and drug resistance

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2805%2970141-9

7 January 2021

The hepatitis B virus polymerase mutation rtV173L is selected during lamivudine therapy and enhances viral replication in vitro.

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2805%2970141-9

7 January 2021

Effect of the G1896A precore mutation on drug sensitivity and replication yield of lamivudine-resistant HBV in vitro

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2805%2970141-9

7 January 2021

Factors associated with hepatitis B virus DNA breakthrough in patients receiving prolonged lamivudine therapy.

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2805%2970141-9

7 January 2021

Prevalence and characterization of lamivudine-resistant hepatitis B virus mutations in HIV-HBV co-infected individuals

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2805%2970141-9

7 January 2021

Molecular anatomy and pathophysiologic implications of drug resistance in hepatitis B virus infection

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2805%2970141-9

7 January 2021

Subtype-dependent response of hepatitis B virus during the early phase of lamivudine treatment

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2805%2970141-9

7 January 2021

Is hepatitis B virus subtype testing useful in predicting virological response and resistance to lamivudine?

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2805%2970141-9

7 January 2021

Chronic active hepatitis B exacerbations in human immunodeficiency virus-infected patients following development of resistance to or withdrawal of lamivudine

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2805%2970141-9

7 January 2021

YMDD-mutant HBV strain as a cause of liver failure in an HIV-infected patient

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2805%2970141-9

7 January 2021

Prevalence and clinical correlates of YMDD variants during lamivudine therapy for patients with chronic hepatitis B.

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2805%2970141-9

7 January 2021

Acute exacerbation and hepatitis B virus clearance after emergence of YMDD motif mutation during lamivudine therapy

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2805%2970141-9

7 January 2021

Efficacy of long-term lamivudine monotherapy in patients with hepatitis B e antigen-negative chronic hepatitis B.

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2805%2970141-9

7 January 2021

Long-term safety of lamivudine treatment in patients with chronic hepatitis B.

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2805%2970141-9

7 January 2021

Clinical outcome and virologic profiles of severe hepatitis B exacerbation due to YMDD mutations.

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2805%2970141-9

7 January 2021

Reactivation of hepatitis B in patients with human immunodeficiency virus infection treated with combination antiretroviral therapy

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2805%2970141-9

7 January 2021

Hepatitis B exacerbation with a precore mutant virus following withdrawal of lamivudine in a human immunodeficiency virus-infected patient

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2805%2970141-9

7 January 2021

Histological outcome during long-term lamivudine therapy.

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2805%2970141-9

7 January 2021

Adefovir dipivoxil alone or in combination with lamivudine in patients with lamivudine-resistant chronic hepatitis B.

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2805%2970141-9

7 January 2021

EASL International Consensus Conference on Hepatitis B. 13-14 September, 2002: Geneva, Switzerland. Consensus statement (short version).

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2805%2970141-9

7 January 2021

Consensus conference on chronic viral hepatitis and HIV infection: updated Spanish recommendations.

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2805%2970141-9

7 January 2021

Prospective comparison of transient elastography, Fibrotest, APRI, and liver biopsy for the assessment of fibrosis in chronic hepatitis C.

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2805%2970141-9

7 January 2021

Interferon alfa for patients with clinically apparent cirrhosis due to chronic hepatitis B

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2805%2970141-9

7 January 2021

Low-dose, titratable interferon alfa in decompensated liver disease caused by chronic infection with hepatitis B virus

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2805%2970141-9

7 January 2021

Long-term additional lamivudine therapy enhances durability of lamivudine-induced HBeAg loss: a prospective study

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2805%2970141-9

7 January 2021

Inhibitory activity of dioxolane purine analogs on wild-type and lamivudine-resistant mutants of hepadnaviruses

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2805%2970141-9

7 January 2021

10.1016/S1473-3099(05)70141-9

Identifiers

DOI

1 reference

12 August 2017

1 reference

PubMed ID

15919623